Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (201-210 of 312) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Commentary on Novitas LCDYair Lotan, Daniel A Barocas, Sam S Chang, et al.
European Urology|May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortMatthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Prostate Cancer and Prostatic Diseases|August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and riskArun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Medical Oncology (Northwood, London, England)|March 21, 2018
Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspectiveJuan Pablo Sade, Carlos Alberto Vargas Báez, Martin Greco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Oncotarget|June 2, 2018
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarkerRachel A Levin, Maria E Lund, Quach Truong, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized TrialEmmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, et al.
Pageof 32

Showing results (201-210 of 312) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Commentary on Novitas LCDYair Lotan, Daniel A Barocas, Sam S Chang, et al.
European Urology|May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer CohortMatthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Prostate Cancer and Prostatic Diseases|August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and riskArun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Medical Oncology (Northwood, London, England)|March 21, 2018
Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspectiveJuan Pablo Sade, Carlos Alberto Vargas Báez, Martin Greco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Oncotarget|June 2, 2018
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarkerRachel A Levin, Maria E Lund, Quach Truong, et al.
The Lancet. Oncology|May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trialKarim Fizazi, Michael J Morris, Neal D Shore, et al.
The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized TrialEmmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, et al.
Pageof 32